Paternal preconception donepezil exposure enhances learning in offspring

Guangyuan Fan1, Tao Pan1, Xingyu Ji1

  • 1School of Basic Medical Sciences, State Key Laboratory of Medical Neurobiology, MOE Frontiers Center for Brain Science, Institutes of Brain Science, Fudan University, Shanghai, 200032, China.

PubMed

Insights

Paternal use of donepezil, a cognition-enhancing drug, may improve offspring learning and memory. This study in rats suggests potential benefits through nonneural pathways, warranting further investigation.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Genetics

Background:

  • Parental use of CNS-targeting medications can impact offspring development.
  • Donepezil, a cholinesterase inhibitor, enhances cognition.
  • The influence of paternal donepezil exposure on offspring is unexplored.

Purpose of the Study:

  • To investigate the effects of paternal donepezil administration on offspring learning and memory.
  • To explore potential molecular mechanisms underlying these effects.

Main Methods:

  • Male rats received oral donepezil (4 mg/kg) for 21 days before breeding.
  • Offspring (F1 generation) were assessed using behavioral tests (novel object recognition, Y maze, operant learning).
  • Transcriptomic analysis of hippocampal tissue was performed.

Main Results:

  • Paternal donepezil exposure enhanced learning and short-term memory in both male and female F1 offspring.
  • Transcriptomic analysis revealed alterations in extracellular matrix-associated genes in the F1 hippocampus.
  • Potential core genes linking to intelligence were identified.

Conclusions:

  • Paternal donepezil exposure may enhance offspring cognitive abilities.
  • The mechanism may involve nonneural, extracellular targets in the brain.
  • Further research is needed to confirm transgenerational effects.
Abstract

Related Concept Videos

Long-term Potentiation01:35

Long-term Potentiation

Long-term potentiation, or LTP, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTP is the process of synaptic strengthening that occurs over time between pre- and postsynaptic neuronal connections. The synaptic strengthening of LTP works in opposition to the synaptic weakening of long-term depression (LTD) and together are the main mechanisms that underlie learning and memory.
Long-term Potentiation01:25

Long-term Potentiation

Long-term potentiation, or LTP, is one of the ways by which synaptic plasticity—changes in the strength of chemical synapses—can occur in the brain. LTP is the process of synaptic strengthening that occurs over time between pre and postsynaptic neuronal connections. The synaptic strengthening of LTP works in opposition to the synaptic weakening of long-term depression (LTD) and together are the main mechanisms that underlie learning and memory.
Hebbian LTP
LTP can occur when presynaptic neurons...
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
Alzheimer Disease l: Introduction01:29

Alzheimer Disease l: Introduction

Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...